NCT02215863View on ClinicalTrials.gov

Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years

PHASE4CompletedINTERVENTIONAL
Enrollment

1,195

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
InfluenzaStreptococcus Pneumoniae
Interventions
BIOLOGICAL

Fluad and Prevenar13

BIOLOGICAL

Fluad

BIOLOGICAL

Prevenar13

Trial Locations (3)

Unknown

Korea University Ansan Hospital, Ansan

Hallym University Gangnam Sacred Hospita, Seoul

Catholic University Medical College, St. Vincent's Hospital, Suwon

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Korea University Guro Hospital

OTHER

NCT02215863 - Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years | Biotech Hunter | Biotech Hunter